|
|
|
|
|
22.12.25 - 15:06
|
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer (Business Wire)
|
|
|
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Board of Directors has decided to commence a cash tender offer as part of its plan to “go private” in lieu of the previously announced reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500.
Voluntary Self Tender consists of acquiring up to 300,000 shares at $3.50 price per share
While the Board of Directors believed that the reverse stock split transaction was in the best interest of the Company and its stockholders at the time of its proposal, upon review and careful consideration, further discussions with management and its advisors and other relevant factors, the Board of Directors has determined that the costs of the proposed reverse stock split transaction ($3.50 per share for fractional shar...
|
|
|
|
|
13.11.25 - 22:06
|
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates (Business Wire)
|
|
|
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended September 30, 2025, and recent updates.
First Quarter Fiscal Year 2026 and Subsequent Highlights:
On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose (“SAD”) study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant is under development for treatment of acute cannabis-induced toxicity in children. The study will investigate the safety, tolerability, and pharmacokinetics of selonabant administered intravenously in healthy adult subjects aged 18 to 30 years. The randomized, double-blind, placebo-controlled study design was cleared by the FDA and is being conducted at a single Phase 1 clinical study site.
Anebulo has been ...
|
|
|
29.09.25 - 22:06
|
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates (Business Wire)
|
|
|
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three and twelve months ended June 30, 2025, and recent updates.
Fourth Quarter Fiscal Year 2025 and Subsequent Highlights:
On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose (“SAD”) study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant is under development for treatment of acute cannabis-induced toxicity in children. The study will investigate the safety, tolerability, and pharmacokinetics of selonabant administered intravenously in healthy adult subjects aged 18 to 25 years. The randomized, double-blind, placebo-controlled study design was cleared by the FDA and is being conducted at a single Phase 1 clinical study site in Austin, ...
|
|
|
|
|
23.07.25 - 14:27
|
XFRA: 214: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
ANEBULO PHARMAC. DL-,001 214 US0345691036
AB/FROM ONWARDS 23.07.2025 14:22 CET...
|
|
|
23.07.25 - 13:36
|
XFRA: 214: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
ANEBULO PHARMAC. DL-,001 214 US0345691036 BAW/UFN...
|
|
|
|
|
|
|
13.05.25 - 22:09
|
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates (Business Wire)
|
|
|
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2025, and recent updates.
Third Quarter Fiscal Year 2025 and Subsequent Highlights:
Anebulo is prioritizing the advancement of an intravenous selonabant as a potential treatment for pediatric patients with cannabis-induced Central Nervous System (“CNS”) depression.
The Company plans to begin dosing healthy adult volunteers in its Phase 1 single ascending dose (“SAD”) study of intravenous selonabant in the third quarter of calendar 2025.
“We anticipate initiating our Phase 1 SAD study of intravenous selonabant in healthy adults aged 18 to 25 years in the third quarter of calendar 2025,” commented Richie Cunningham, Chief Executive Officer of Anebulo.
Cunningham continued, “There is...
|
|
|
|
|
|
|
14.02.25 - 22:09
|
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates (Business Wire)
|
|
|
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2024, and recent updates.
Second Quarter Fiscal Year 2025 and Subsequent Highlights:
In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing. FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication. Anebulo plans to begin its Phase 1 single ascending dose (“SAD”) study of intravenous selonabant in healthy adults in 1H25
In December 2024, Anebulo entered into a definitive stock purchase agreement with 22NW Fund, LP (“22NW”), a company controlled by one of i...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
